Andy Plump teams with MD An­der­son on the race to cell ther­a­py 2.0 — and they’re al­ready plan­ning a piv­otal

6 years ago
Deals
R&D

It took a 3-year strug­gle, but No­var­tis fi­nal­ly gets a green light on their copy­cat to Am­gen's big block­buster

6 years ago
R&D

Unum drops an­oth­er pro­gram for trou­bled PhI ther­a­py, mov­ing its eggs to the sol­id tu­mor bas­ket

6 years ago
R&D

As CRISPR hori­zons cloud, a start­up fo­cus­es on the next big thing with pow­er­house po­ten­tial — the RNA edit­ing ...

6 years ago
Startups

Is FDA do­ing enough to bring biosim­i­lars to mar­ket? Ex­perts dis­cuss

6 years ago
Pharma
FDA+

Make room for poop trans­plants, even if a stool-based ther­a­py is even­tu­al­ly ap­proved — in­sist doc­tors and pa­tients ...

6 years ago
FDA+

Sino Bio­pharm, Or­biMed back Mer­ck-part­nered Ake­so­bio's bet on made-in-Chi­na an­ti­bod­ies

6 years ago
Financing
China

Tmu­ni­ty teams up with On­co­ra Med­ical; T3D re­ceives ad­di­tion­al fund­ing for Alzheimer's study

6 years ago
News Briefing

FDA to Aveo: That's still a 'no' on ti­vo. Aveo: We'll be back.

6 years ago
R&D

As­traZeneca wins ku­dos for pipeline turn­around in a new rank­ing of the top 10 R&D play­ers in the bio­phar­ma world

6 years ago
R&D
Pharma

Sanofi shows off pos­i­tive PhI­II tri­al re­sults for Tou­jeo, open­ing the door to a new group of di­a­betes pa­tients

6 years ago
R&D

As re­sis­tance to stan­dard an­tibi­otics grows, Red­Hill's H. py­lori reg­i­men se­cures FDA ap­proval

6 years ago
R&D
FDA+

Halozyme's lead drug flops in PhI­II, forc­ing CEO to ax 160 and re­set fo­cus on tech plat­form

6 years ago
R&D

Alzheimer's stun­ner: Chi­nese biotech wins OK for a new drug on pos­i­tive da­ta — and they have some high-pro­file ...

6 years ago
China
FDA+

Worth­less? Short at­tack on Fi­bro­Gen claims their ane­mia drug roxa has a lethal Achilles’ heel — and it’s go­ing ...

6 years ago
R&D
Pharma

Right on dead­line, Trump taps Stephen Hahn as new FDA com­mish. Now what?

6 years ago
People
Pharma

Gilead­'s ex-in­vestor re­la­tions chief takes CFO job at Sang­amo; For­mer GE Health­care ex­ec takes the helm at Vec­tura ...

6 years ago
Peer Review

No­vo dumps pro­posed Ry­bel­sus suc­ces­sor for new­er mod­el

6 years ago
R&D

Da­ta sug­gest gene, cell ther­a­py tri­al ini­ti­a­tions in Eu­rope lag be­hind North Amer­i­ca — here's why

6 years ago
R&D
FDA+

Eight years af­ter a land­mark buy­out, Sanofi agrees to pay ag­griev­ed Gen­zyme share­hold­ers $315M to set­tle ...

6 years ago
R&D
Pharma

Paratek's top an­tibi­ot­ic fails to clear a key com­pet­i­tive hur­dle in head-to-head stud­ies

6 years ago
R&D

No­var­tis' Cosen­tyx miss­es main goal in head-to-head tri­al with Ab­b­Vie's Hu­mi­ra

6 years ago
R&D

No­var­tis ad­mits to ‘mis­take’ af­ter par­tial clin­i­cal hold placed on Zol­gens­ma tri­al

6 years ago
FDA+

Am­gen takes a $2.7B stake in BeiGene, gain­ing a promi­nent al­ly in Chi­na to help seize a lead­ing role in can­cer drug ...

6 years ago
Deals
China
First page Previous page 883884885886887888889 Next page Last page
A service from the Financial Times